ERBB2 and breast cancer: Finally, HER2 IHC 3+ BC showed pCR in the 93.7% of tumors and in the 86.7% of lymph node after neoadjuvant therapy vs 6.3% and 13.3% of HER2 IHC 2+/SISH+ BC, respectively (both P < 0.001).